An inhaled galectin 3 inhibitor in COVID-19 pneumonitis. A phase Ib/IIa randomized controlled clinical trial (DEFINE) (2022)

First Author: Guaghan, EE
Attributed to:  Optimising Innate Host Defence to Combat Antimicrobial Resistance funded by MRC

Abstract

No abstract provided

Bibliographic Information

Type: Journal Article/Review

Parent Publication: Am J Respir Crit Care Med